Physicians' Academy for Cardiovascular Education

ISA 2015

The 17th International Symposium on Atherosclerosis (ISA2015) reflected the start of a new era in atherosclerosis research, combining insights in lipid metabolism, inflammation, epidemiology, genetics, imaging and more, and translating this into novel therapeutic strategies.

Inflammation, the immune system and atherosclerosis

10' education - July 7, 2015 - Amsterdam IAS
##SCROLLER_ITEMS_FULL_TITLE##

Pharmacodynamics of investigational pre-beta HDL-mimicking agent

3' education - May 24, 2015 - ISA2015, Amsterdam - Eralp Bellibas
##SCROLLER_ITEMS_FULL_TITLE##

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##SCROLLER_ITEMS_FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##SCROLLER_ITEMS_FULL_TITLE##

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby
##SCROLLER_ITEMS_FULL_TITLE##

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##SCROLLER_ITEMS_FULL_TITLE##

Persistent lipid changes with long-term treatment with mipomersen

3' education - May 24, 2015 - ISA2015, Amsterdam - dr. Paul Barton Duell
##SCROLLER_ITEMS_FULL_TITLE##

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##SCROLLER_ITEMS_FULL_TITLE##

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##SCROLLER_ITEMS_FULL_TITLE##

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
##SCROLLER_ITEMS_FULL_TITLE##

Ezetimibe does not disturb glycaemic control

3' education - June 16, 2015 - ISA2015, Amsterdam - Peter Toth
##SCROLLER_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

Lowering triglycerides while raising LDL-c: is this a problem?

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Børge Nordestgaard
##SCROLLER_ITEMS_FULL_TITLE##

Increase in LDL may not always be associated with increase in CV risk

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
##SCROLLER_ITEMS_FULL_TITLE##

Collective amnesia on dietary fats and LDL-c

3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Prof. Martijn Katan
##SCROLLER_ITEMS_FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
##SCROLLER_ITEMS_FULL_TITLE##

John Chapman awarded for research on cholesterol particles

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Prof. John Chapman, Paris, France
##SCROLLER_ITEMS_FULL_TITLE##

Harry Davis awarded with first Endo Award for discovery of ezetimibe

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Harry Davis
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein

Inflammation, the immune system and atherosclerosis

10' education - July 7, 2015 - Amsterdam IAS

This discussion combines the mechanistic insights into the inflammatory component in atherogenesis of Jon Laman with the clinical perspective of Wolfgang Koenig. They discuss how inflammation reseach may change CV treatment approaches in the future.

DM subgroup analysis in PEGASUS-TIMI 54 trial shows significant MI risk reduction

Literature - June 16, 2016 - Bhatt DL, et al. J Am Coll Cardiol 2016

In the PEGASUS-TIMI 54 trial, ticagrelor on top of aspirin significantly reduced absolute risk of recurrent ischemic events, but increased the risk of TIMI major bleeding in DM patients with a history of MI.

Tomorrow's specialists meet today's experts

Oct. 14, 2015

Several animated discussions between young scientists and international leaders in cardiovascular medicine were recorded in the PACE-studio during ISA2015.

Pharmacodynamics of investigational pre-beta HDL-mimicking agent

3' education - May 24, 2015 - ISA2015, Amsterdam - Eralp Bellibas
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Eralp Bellibas shares pharmacokinetic and pharmacodynamic data of the apoA1-Milano-POPC (MDCO216), developed to mimic pre-beta HDL molecules, which was more potent at increasing cholesterol efflux in CAD patients than in healthy volunteers.

Statins are enough for the prevention of CVD

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
##OVERVIEW_ITEMS_KEY_PHRASE##

Prof. Ray defends the proposition 'Statins are enough for the prevention of CVD' and considers the opposing standpoint in the plenary 'Controversy session' entitled 'Statin therapy vs. novel interventions'. Ray thinks more CVD could be prevented if more people globally would have access to statins. Is it time to add statins to drinking water, then?

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA 2015 Joost Besseling and colleagues developed a new prediction model to determine which patients might have a disease-causing FH mutation. The model works particularly well in young patients with familial hypercholesterolaemia.

Studying the cardioprotective properties of the phosphatidylserine-component of HDL

3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Kontush shared data of a study into the lipidome of HDL particles. HDL particles with phosphatidylserine showed more cardioprotective properties, including antiinflammatory activity, than those without phospatidylserine, both in vitro and in mice.

The changing character of atherosclerotic disease

3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA 2015 Prof. Peter Libby recapitulates evolving insights into the mechanism of acute coronary syndromes, and how we may be shifting from a predominance of plaque ruptures towards superficial erosion as the cause of ACS.

Patients confident to use injectable PCSK9-inhibitor via self-injection

3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Bertrand Cariou presents data of a study that investigated the willingness of patients and physicians to use self-injections (either by prefilled pen or a prefilled syringe) to administer the PCSK9-antibody alirocumab.

Persistent lipid changes with long-term treatment with mipomersen

3' education - May 24, 2015 - ISA2015, Amsterdam - dr. Paul Barton Duell
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Dr. Barton Duell presented efficacy and safety data of 4.5 years of treatment with mipomersen, showing sustained lowering of LDL-c, Lp(a) and apoB, without revealing new safety concerns.

The effects of a PCSK9-inhibitor on various lipid fractions

3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Gisette Reyes-Soffer shares the findings on the effect of PCSK9-inhibitor alirocumab on VLDL, IDL, LDL and apoB-metabolism in healthy volunteers.

New, more potent chemical agent to lower triglyceride levels

3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
##OVERVIEW_ITEMS_KEY_PHRASE##

ISA2015 | Clinical Breakthroughs Harold Bays shares the results of treatment with a new potent chemical entity, cosabutate, hich safely modifies triglyceride and lipid fraction levels in patients with hypertriglyceridaemia.